Parkinson's disease
Last updated 3 Apr 2025
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Parkinson's disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.
Video picks for Genetic conditionsVideo library
Description
Parkinson's disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.
Often the first symptom of Parkinson's disease is trembling or shaking (tremor) of a limb, especially when the body is at rest. Typically, the tremor begins on one side of the body, usually in one hand. Tremors can also affect the arms, legs, feet, and face. Other characteristic symptoms of Parkinson's disease include rigidity or stiffness of the limbs and torso, slow movement (bradykinesia) or an inability to move (akinesia), and impaired balance and coordination (postural instability). These symptoms worsen slowly over time.
Parkinson's disease can also affect emotions and thinking ability (cognition). Some affected individuals develop psychiatric conditions such as depression and visual hallucinations. People with Parkinson's disease also have an increased risk of developing dementia, which is a decline in intellectual functions including judgement and memory.
Generally, Parkinson's disease that begins after age 50 is called late-onset disease. The condition is described as early-onset disease if signs and symptoms begin before age 50. Early-onset cases that begin before age 20 are sometimes referred to as juvenile-onset Parkinson's disease.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal dominant+1 affected parent; Autosomal recessive; Pattern unknown. More than one pattern can apply in different cases.
Related genes
Other names
Parkinson disease
PD
Primary parkinsonism
Patient picks for Genetic conditions

Brain and nerves
Parkinson's disease
The main symptoms of Parkinson's disease are usually stiffness, shaking (tremor), and slowness of movement. People with Parkinson's may also develop other symptoms (listed below). Symptoms typically become gradually worse over time. Treatment often provides good relief of symptoms for several years.
by Dr Colin Tidy, MRCGP

Brain and nerves
Could it be Parkinson's disease?
Parkinson's disease affects the brain cells and nerves that help you move your muscles in a co-ordinated way. It mostly affects people over 50 - about 1 in 200 people in their 60s and 1 in 50 over-80s. There are exceptions - Michael J. Fox developed the condition young - and in younger people, it's more likely to run in families.
by Dr Sarah Jarvis

Brain and nerves
What worsens Parkinson's disease?
Parkinson's disease is a progressive loss of certain nerve cells (dopaminergic cells) within specific areas of the brain (the substantia nigra). It is not known exactly what causes Parkinson's disease but it seems to be a combination of genetic and environmental factors.
by Dr Colin Tidy, MRCGP

Brain and nerves
Which therapies can ease Parkinson's disease symptoms?
If you're living with Parkinson's disease, symptoms affecting both your mobility and mental state can make daily life a struggle. There are several supportive therapies that your specialist healthcare nurse may recommend.
by Amberley Davis

Brain and nerves
What is the link between Parkinson's disease and dementia?
Parkinson's and dementia are separate conditions, with many people developing one without the other. This said, people with Parkinson's have a higher risk of dementia, particularly during old age. The two main types of dementia that people with Parkinson's can develop are 'Parkinson's dementia' and 'dementia with Lewy bodies'.
by Amberley Davis

Brain and nerves
Prostate cancer drug could slow down Parkinson's disease
A study has found that a drug used to treat an enlarged prostate could also slow the progression of Parkinson's disease.
by Milly Evans
Related patient information and medicines

Patient information leaflet
Parkinson's disease
The main symptoms of Parkinson's disease are usually stiffness, shaking (tremor), and slowness of movement. What is Parkinson's disease. Parkinson's disease is a progressive neurological degeneration of certain cells (called dopaminergic cells) within a specific part of the brain (substantia nigra). Parkinson's disease symptoms The brain cells and.

Medicine leaflet
Apomorphine for Parkinson's disease
Apomorphine is used for 'off' episodes in Parkinson's disease. About apomorphine Type of medicine Dopamine-receptor agonist Used for Parkinson's disease Also called APO-go®, Dacepton® Available as Pen injector, cartridges or pre-filled syringe Parkinson's disease Parkinson's disease is a disorder of the brain. ...on of your brain will have become.

Medicine leaflet
Tolcapone for Parkinson's disease
Tolcapone can cause liver problems. About tolcapone Type of medicine A dopaminergic medicine called a catechol-O-methyltransferase inhibitor Used for Parkinson's disease Also called Tasmar® Available as Tablets Parkinson's disease Parkinson's disease affects the way your brain co-ordinates the movements of your muscles. A combination of the.

Medicine leaflet
Co-beneldopa for Parkinson's disease
Co-beneldopa is a medicine which has been prescribed for many years for people with Parkinson's disease. About co-beneldopa Type of medicine A dopaminergic medicine Used for Parkinson's disease in people over 25 years of age Also called Madopar® Available as Capsules, dispersible tablets and prolonged-release capsules You will have been prescribed.

Medicine leaflet
Selegiline for Parkinson's disease
About selegiline Type of medicine A monoamine-oxidase-B inhibitor Used for Parkinson's disease Also called Eldepryl® Available as Tablets The symptoms of Parkinson's disease Parkinson's disease - tremor, stiffness and slow movement - are due to there being less of a chemical called dopamine in your brain. Selegiline works by increasing the effect.

Patient information leaflet
Alzheimer's disease
People who have experienc... Lifestyle factors that also increase the risk of cardiovascular disease Cardiovascular disease and cerebrovascular disease Stroke - for example, smoking, lack of physical exercise, and an unhealthy diet. Parkinson's disease Parkinson's disease. People with Down's syndrome Down's syndrome. ServiceUpsellPlaceholder.
Further reading and references
- Parkinson's disease; MedlinePlus, National Library of Medicine.
- Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 2006 Mar;7(3):207-19. doi: 10.1038/nrn1868.
- Cookson MR, Bandmann O. Parkinson's disease: insights from pathways. Hum Mol Genet. 2010 Apr 15;19(R1):R21-7. doi: 10.1093/hmg/ddq167. Epub 2010 Apr 26.
- Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev. 2011 Oct;91(4):1161-218. doi: 10.1152/physrev.00022.2010.
- Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006 Apr;7(4):306-18. doi: 10.1038/nrg1831.
- Gasser T. Genetics of Parkinson's disease. Curr Opin Neurol. 2005 Aug;18(4):363-9. doi: 10.1097/01.wco.0000170951.08924.3d.
- Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol. 2006 Oct;60(4):389-98. doi: 10.1002/ana.21022.
- Huang Y, Cheung L, Rowe D, Halliday G. Genetic contributions to Parkinson's disease. Brain Res Brain Res Rev. 2004 Aug;46(1):44-70. doi: 10.1016/j.brainresrev.2004.04.007.
- Jain S, Wood NW, Healy DG. Molecular genetic pathways in Parkinson's disease: a review. Clin Sci (Lond). 2005 Oct;109(4):355-64. doi: 10.1042/CS20050106.
- Klein C, Schneider SA, Lang AE. Hereditary parkinsonism: Parkinson disease look-alikes--an algorithm for clinicians to "PARK" genes and beyond. Mov Disord. 2009 Oct 30;24(14):2042-58. doi: 10.1002/mds.22675.
- Lewthwaite AJ, Nicholl DJ. Genetics of parkinsonism. Curr Neurol Neurosci Rep. 2005 Sep;5(5):397-404. doi: 10.1007/s11910-005-0064-6.
- Morris HR. Genetics of Parkinson's disease. Ann Med. 2005;37(2):86-96. doi: 10.1080/07853890510007269.
- Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat. 2010 Jul;31(7):763-80. doi: 10.1002/humu.21277.
- Pankratz N, Foroud T. Genetics of Parkinson disease. NeuroRx. 2004 Apr;1(2):235-42. doi: 10.1602/neurorx.1.2.235.
- Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004 May 29;363(9423):1783-93. doi: 10.1016/S0140-6736(04)16305-8.
- Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Durr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M, Tan EK, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, Ziegler SG. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009 Oct 22;361(17):1651-61. doi: 10.1056/NEJMoa0901281.
- Singleton AB. Altered alpha-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. Trends Neurosci. 2005 Aug;28(8):416-21. doi: 10.1016/j.tins.2005.05.009.
- Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat. 2007 Jul;28(7):641-53. doi: 10.1002/humu.20507.
- Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003 Jun 1;157(11):1015-22. doi: 10.1093/aje/kwg068.
- Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med. 2004 Jul;10 Suppl:S58-62. doi: 10.1038/nm1068.
- von Bohlen und Halbach O, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol. 2004 Jun;73(3):151-77. doi: 10.1016/j.pneurobio.2004.05.002.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

